Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Phamacokinetics and safety profiles of DA-5213 10mg in Healthy subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A | Experimental |
| |
| Sequence B | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DA-5213 10mg | Drug | single dose administration (one tablet once a day) |
|
| Measure | Description | Time Frame |
|---|---|---|
| AUCt | area under the curve | [Time Frame: pre-dose~48 hours post-dose] |
| Cmax | maximum plasma concentration | [Time Frame: pre-dose~48 hours post-dose] |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Central Hospital | Siheung-si | Gyeonggi-do | 15079 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| DA-5213-R 10mg | Drug | single dose administration (one tablet once a day) |
|